Algeta

Oslo, Norway Founded: 1997 • Age: 29 yrs Acquired By Bayer
Alpha-emitting pharmaceuticals are developed for cancer treatment.
Request Access

About Algeta

Algeta is a company based in Oslo (Norway) founded in 1997 was acquired by Bayer in December 2013.. Algeta has raised $29 million across 1 funding round from investors including Bayer, Selvaag and SR One. Algeta operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Oslo, Norway
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Algeta As
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $29 M (USD)

    in 1 rounds

  • Latest Funding Round
    $29 M (USD), Series A

    Sep 07, 2005

  • Investors
    Bayer

    & 4 more

  • Employee Count
    Employee Count
  • Acquired by
    Bayer

    (Dec 19, 2013)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Algeta

Algeta has successfully raised a total of $29M through 1 strategic funding round. The most recent funding activity was a Series A round of $29 million completed in September 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $29.0M
  • First Round

    (07 Sep 2005)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2005 Amount Series A - Algeta Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Algeta

Algeta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, Selvaag and SR One. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
A biotechnology venture capital firm investing in innovative science.
Founded Year Domain Location
Wealth management and investment services are provided by NorgesInvestor.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Algeta

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Algeta

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Algeta Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Algeta

Algeta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Algeta

Frequently Asked Questions about Algeta

When was Algeta founded?

Algeta was founded in 1997 and raised its 1st funding round 8 years after it was founded.

Where is Algeta located?

Algeta is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.

Is Algeta a funded company?

Algeta is a funded company, having raised a total of $29M across 1 funding round to date. The company's 1st funding round was a Series A of $29M, raised on Sep 07, 2005.

What does Algeta do?

Algeta was founded in 1997 in Oslo, Norway, as an oncology-focused company. Targeted therapies based on an alpha-pharmaceutical platform were developed for cancer patients. The lead product, radium-223 dichloride, was advanced through Phase III trials for castration-resistant prostate cancer with bone metastases. Thorium-227 conjugates linked to tumor-targeting molecules were explored in preclinical stages. Acquisition by Bayer occurred in December 2013.

Who are the top competitors of Algeta?

Algeta's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Who are Algeta's investors?

Algeta has 5 investors. Key investors include Bayer, Selvaag, SR One, NorgesInvestor, and Healthcap.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available